头孢甲肟（SCE 1365）治疗68例败血症的细菌学、临床及动力学评价。一项多中心试验
[Bacteriologic, clinical and kinetic evaluation of cefmenoxime (SCE 1365) in the treatment of 68 cases of septicemia. A multicenter trial].
作者信息
Bryskier A, Sollet J P, Bleichner G, Segrestaa J M, Guerin J M, Dureux J B, Canton P, Veyssier P, Lallement P Y, Mottin J
出版信息
Pathol Biol (Paris). 1984 Jun;32(5 Pt 2):547-51.
PMID:6087250
Abstract
Cefmenoxime (SCE 1365), a new broad-spectrum, third generation cephalosporin was used in the treatment of 68 patients with bacteremia. Cefmenoxime was given as monotherapy to 63 patients in a mean daily dosage of 3 g (range: 1 to 6 g). 63 successes were recorded. Results were inconclusive in the remaining five cases. General and biological tolerance of cefmenoxime was excellent.
摘要
头孢甲肟（SCE 1365）是一种新型广谱第三代头孢菌素，用于治疗68例菌血症患者。63例患者采用头孢甲肟单一疗法，平均日剂量为3克（范围：1至6克）。记录到63例治疗成功。其余5例结果尚无定论。头孢甲肟的总体耐受性和生物学耐受性良好。
Zotero 插件